Before we begin, if you do not already have a copy, the third quarter earnings release, supplemental information, and related Form 8-K filed with the SEC are available on our website at encompasshealth.com. On page two of the supplemental information, you will find the Safe Harbor statements, which are also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements such as guidance and growth projections, which are subject to risks and uncertainties, many of which are beyond our control. You are cautioned not to place undue reliance on the estimates, projections, guidance, and other forward-looking information presented, which are based on current estimates of future events and speak only as of today.
Revenue in Q3 increased 9.4% and adjusted EBITDA grew 11.4%, contributing to year to date revenue growth of 10.6% and adjusted EBITDA growth of 14.5%. Going largely to our Q3 results, we have again increased our 2025 guidance. Doug will cover the details of the quarter and guidance in his comments. We continue to invest in our clinical staff by providing professional growth and development opportunities such as our career ladder programs.
The demand for inpatient rehabilitation services remains considerably underserved and continues to grow as the U.S. The Medicare beneficiary population is the fastest growing segment of the U.S. As a result, the demand for treatment of the complex medical conditions such as stroke necessitating IRF care intensity remain significantly underserved. Our pipeline of announced new hospitals with opening dates beyond 2025 currently consists of 14 hospitals with 690 beds with an active pipeline, more than 40 projects.